Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

Patients with non-small-cell lung cancer (NSCLC) appear to gain particular benefit from treatment with epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKI) if their disease tests positive for EGFR activating mutations. Recently, several large, controlled, phase III studies have b...

Descripción completa

Detalles Bibliográficos
Autores principales: Paz-Ares, Luis, Soulières, Denis, Moecks, Joachim, Bara, Ilze, Mok, Tony, Klughammer, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190899/
https://www.ncbi.nlm.nih.gov/pubmed/25100284
http://dx.doi.org/10.1111/jcmm.12278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4190899/
https://www.ncbi.nlm.nih.gov/pubmed/25100284
http://dx.doi.org/10.1111/jcmm.12278

Ejemplares similares